company background image
TRX logo

Tissue Regenix Group AIM:TRX Stock Report

Last Price

UK£0.63

Market Cap

UK£44.0m

7D

-1.6%

1Y

8.7%

Updated

28 Mar, 2024

Data

Company Financials +

Tissue Regenix Group plc

AIM:TRX Stock Report

Market Cap: UK£44.0m

TRX Stock Overview

Tissue Regenix Group plc, a medical technology company, develops and commercializes platform technologies in the field of bone graft substitutes and soft tissue in the United States and internationally.

TRX fundamental analysis
Snowflake Score
Valuation3/6
Future Growth4/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Tissue Regenix Group plc Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Tissue Regenix Group
Historical stock prices
Current Share PriceUK£0.63
52 Week HighUK£0.73
52 Week LowUK£0.48
Beta1.48
1 Month Change-8.76%
3 Month Change20.19%
1 Year Change8.70%
3 Year Change-5.30%
5 Year Change-90.91%
Change since IPO-92.86%

Recent News & Updates

Tissue Regenix Group plc's (LON:TRX) Shares Bounce 25% But Its Business Still Trails The Industry

Feb 25
Tissue Regenix Group plc's (LON:TRX) Shares Bounce 25% But Its Business Still Trails The Industry

Recent updates

Tissue Regenix Group plc's (LON:TRX) Shares Bounce 25% But Its Business Still Trails The Industry

Feb 25
Tissue Regenix Group plc's (LON:TRX) Shares Bounce 25% But Its Business Still Trails The Industry

Is Tissue Regenix Group (LON:TRX) A Risky Investment?

Jun 10
Is Tissue Regenix Group (LON:TRX) A Risky Investment?

Tissue Regenix Group plc (LON:TRX): Are Analysts Optimistic?

Apr 02
Tissue Regenix Group plc (LON:TRX): Are Analysts Optimistic?

Tissue Regenix Group plc (LON:TRX): Are Analysts Optimistic?

Nov 18
Tissue Regenix Group plc (LON:TRX): Are Analysts Optimistic?

Shareholder Returns

TRXGB BiotechsGB Market
7D-1.6%-1.6%0.9%
1Y8.7%-28.9%2.2%

Return vs Industry: TRX exceeded the UK Biotechs industry which returned -27.3% over the past year.

Return vs Market: TRX exceeded the UK Market which returned 2.7% over the past year.

Price Volatility

Is TRX's price volatile compared to industry and market?
TRX volatility
TRX Average Weekly Movement5.4%
Biotechs Industry Average Movement7.9%
Market Average Movement4.8%
10% most volatile stocks in GB Market11.1%
10% least volatile stocks in GB Market2.6%

Stable Share Price: TRX has not had significant price volatility in the past 3 months.

Volatility Over Time: TRX's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
200682Danny Leehttps://www.tissueregenix.com

Tissue Regenix Group plc, a medical technology company, develops and commercializes platform technologies in the field of bone graft substitutes and soft tissue in the United States and internationally. The company operates through dCELL, BioRinse, and GBM-V segments. It also provides dCELL technology, a soft tissue decellularisation process that removes DNA and other cellular material from animal and human soft tissue to repair diseased or damaged body parts; and BioRinse technology, a natural bone filler solution for osteoinductivity to stimulate and regenerate native bone growth.

Tissue Regenix Group plc Fundamentals Summary

How do Tissue Regenix Group's earnings and revenue compare to its market cap?
TRX fundamental statistics
Market capUK£44.01m
Earnings (TTM)-UK£1.36m
Revenue (TTM)UK£23.37m

1.9x

P/S Ratio

-32.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
TRX income statement (TTM)
RevenueUS$29.49m
Cost of RevenueUS$15.45m
Gross ProfitUS$14.04m
Other ExpensesUS$15.75m
Earnings-US$1.71m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.024
Gross Margin47.60%
Net Profit Margin-5.81%
Debt/Equity Ratio20.4%

How did TRX perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.